Astellas Pharma Inc. (4503.T)
Develops and sells prescription drugs treating cancer, eye disease, bladder problems, and other conditions.
2,295.50+0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+45.6%
The outlook
Astellas Pharma trades near the middle of its 52-week range and above both its 50- and 200-day moving averages, reflecting a steady uptrend. Analyst consensus leans toward Buy, with an average price target sitting about 4% above the current level. The stock's valuation remains moderate at 14.2x trailing earnings.
What’s behind the score
Analyst consensusBuy — 2.5 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range66% of the way from its 52-week low to high
Price targetAvg target +4% vs current price
Analyst price target
~12-month · 13 analysts2,388.46average target+4.0% vs now
Now 2,295.50
Low 1,700.00High 3,000.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$4.11T
52-wk high
2,717.00
52-wk low
1,475.00
50-day avg
2,172.50
200-day avg
2,191.32
Trailing P/E
14.2